Andra AP fonden Raises Position in IDEXX Laboratories, Inc. $IDXX

Andra AP fonden lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 533.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,900 shares of the company’s stock after purchasing an additional 25,177 shares during the period. Andra AP fonden’s holdings in IDEXX Laboratories were worth $19,103,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in IDEXX Laboratories by 156.2% during the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after purchasing an additional 884,808 shares during the period. Generation Investment Management LLP purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $304,277,000. Norges Bank bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $221,955,000. JPMorgan Chase & Co. grew its stake in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares during the period. Finally, Schroder Investment Management Group increased its holdings in IDEXX Laboratories by 295.1% in the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after acquiring an additional 235,863 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,873 shares of company stock worth $13,408,523 in the last ninety days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $656.73 on Friday. The business’s 50-day moving average is $672.95 and its 200 day moving average is $668.97. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a market capitalization of $52.29 billion, a P/E ratio of 50.25, a P/E/G ratio of 4.01 and a beta of 1.67. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on IDXX shares. BTIG Research lowered their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. UBS Group cut their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Finally, Morgan Stanley boosted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.